Table 1.
Characteristics | Not treated (n = 7658) | Treated (n = 6341) |
% of the 13 999 patients | 55.7 | 45.3 |
Genotypes 1/4/5/6 (%) | 69.8 | 59.4 |
Genotypes 2/3 (%) | 30.2 | 40.6 |
Age (yr, median) | 44.0 | 41.0 |
BMI (kg/m2, median) | 24.2 | 24.3 |
Gender (male %) | 56.6 | 61.1 |
Regulär employment (%) | 35.3 | 50.2 |
Infection length (yr, median) | 11.0 | 10.0 |
Ultrasound performed (%) | 76.8 | 87.6 |
Liver biopsy performed (%) | 12.8 | 30.2 |
Fibrosis score F 0-1 | 72.8 | 58.6 |
Fibrosis score F 2-4 | 27.2 | 41.4 |
Active drug or alcohol abuse (%) | 28.3 | 13.8 |
HIV co-infection (%) | 6.7 | 3.7 |
Psychiatric disease (%) | 14.8 | 9.2 |
Severe language problems (%) | 9.6 | 10.0 |
Initial HCV-RNA (IU/mL, median) | 482 500 | 500 000 |
ALT (U/L, median) | 61.0 | 78.0 |
Thrombocytes (/μL, median) | 217 000 | 218 000 |
At least on concomitant disease (%) | 62.3 | 42.6 |
BMI: Body mass index; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; ALT: Alanine aminotransferase.